Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019–2021)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019–2021)

Published:2022-03-10 Issue:5 Volume:32 Page:575-589
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Deng Jingjing¹,Cheng Zhengqi²,Long Juyang²,Dömling Alexander³,Tortorella Micky²,Wang Yuanze²

Affiliation:

1. Department of Molecular Genetics, University of Groningen, Groningen, Netherlands

2. Department of Drug Discovery, Bioland Laboratory (Guangzhou Regenerative Medicine and Health - Guangdong Laboratory), Guangzhou, P. R. China

3. Department of Drug Design, University of Groningen, Groningen, Netherlands

Funder

GuangDong Basic and Applied Basic Research Foundation

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2022.2045276

Reference77 articles.

1. Pembrolizumab: First Global Approval

2. Atezolizumab: First Global Approval

3. Avelumab: First Global Approval

4. Durvalumab: First Global Approval

5. Cemiplimab: First Global Approval

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, and optimization of novel PD-L1 inhibitors and the identification of a highly potent and orally bioavailable PD-L1 inhibitor;European Journal of Medicinal Chemistry;2024-11

2. An updated patent review on PD-1/PD-L1 antagonists (2022-present);Expert Opinion on Therapeutic Patents;2024-06-25

3. C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein–Protein Interaction;Molecules;2024-06-04

4. Nonsymmetrically Substituted 1,1′-Biphenyl-Based Small Molecule Inhibitors of the PD-1/PD-L1 Interaction;ACS Medicinal Chemistry Letters;2024-06-03

5. Molecular glues for protein-protein interactions: Progressing toward a new dream;Cell Chemical Biology;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3